Cargando…
A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
Objective. The purpose of this systematic review is to evaluate the evidence of Yiqi Yangyin Huoxue Method for diabetic nephropathy. Methods. 11 electronic databases, through September 2015, were searched to identify randomized controlled trials of Yiqi Yangyin Huoxue Method for diabetic nephropathy...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904113/ https://www.ncbi.nlm.nih.gov/pubmed/27313643 http://dx.doi.org/10.1155/2016/3257603 |
_version_ | 1782437098565926912 |
---|---|
author | Ou, Jiao Ying Huang, Di Wu, Yan Sheng Xu, Lin He, Fei Wang, Hui Ling Shi, Li Qiang Wan, Qiang He, Li Qun Dong Gao, Jian |
author_facet | Ou, Jiao Ying Huang, Di Wu, Yan Sheng Xu, Lin He, Fei Wang, Hui Ling Shi, Li Qiang Wan, Qiang He, Li Qun Dong Gao, Jian |
author_sort | Ou, Jiao Ying |
collection | PubMed |
description | Objective. The purpose of this systematic review is to evaluate the evidence of Yiqi Yangyin Huoxue Method for diabetic nephropathy. Methods. 11 electronic databases, through September 2015, were searched to identify randomized controlled trials of Yiqi Yangyin Huoxue Method for diabetic nephropathy. The quality of the included trials was assessed using the Jadad scale. Results. 26 randomized controlled trials were included in our review. Of all the included trials, most of them were considered as high quality. The aggregated results suggested that Yiqi Yangyin Huoxue Method is beneficial to diabetic nephropathy in bringing down the microalbuminuria (SMD = −0.98, 95% CI −1.22 to −0.74), serum creatinine (SMD = −0.56, 95% CI −0.93 to −0.20), beta-2 microglobulin (MD = 0.06, 95% CI 0.01 to 0.12), fasting plasma glucose (MD = −0.35, 95% CI −0.62 to −0.08), and 2-hour postprandial blood glucose (MD = 1.13, 95% CI 0.07 to 2.20), but not in decreasing blood urea nitrogen (SMD = −0.72, 95% CI −1.47 to 0.02) or 2-hour postprandial blood glucose (SMD = −0.48, 95% CI −1.01 to 0.04). Conclusions. Yiqi Yangyin Huoxue Method should be a valid complementary and alternative therapy in the management of diabetic nephropathy, especially in improving UAER, serum creatinine, fasting blood glucose, and beta-2 microglobulin. However, more studies with long follow-up are warrant to confirm the current findings. |
format | Online Article Text |
id | pubmed-4904113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-49041132016-06-16 A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy Ou, Jiao Ying Huang, Di Wu, Yan Sheng Xu, Lin He, Fei Wang, Hui Ling Shi, Li Qiang Wan, Qiang He, Li Qun Dong Gao, Jian Evid Based Complement Alternat Med Research Article Objective. The purpose of this systematic review is to evaluate the evidence of Yiqi Yangyin Huoxue Method for diabetic nephropathy. Methods. 11 electronic databases, through September 2015, were searched to identify randomized controlled trials of Yiqi Yangyin Huoxue Method for diabetic nephropathy. The quality of the included trials was assessed using the Jadad scale. Results. 26 randomized controlled trials were included in our review. Of all the included trials, most of them were considered as high quality. The aggregated results suggested that Yiqi Yangyin Huoxue Method is beneficial to diabetic nephropathy in bringing down the microalbuminuria (SMD = −0.98, 95% CI −1.22 to −0.74), serum creatinine (SMD = −0.56, 95% CI −0.93 to −0.20), beta-2 microglobulin (MD = 0.06, 95% CI 0.01 to 0.12), fasting plasma glucose (MD = −0.35, 95% CI −0.62 to −0.08), and 2-hour postprandial blood glucose (MD = 1.13, 95% CI 0.07 to 2.20), but not in decreasing blood urea nitrogen (SMD = −0.72, 95% CI −1.47 to 0.02) or 2-hour postprandial blood glucose (SMD = −0.48, 95% CI −1.01 to 0.04). Conclusions. Yiqi Yangyin Huoxue Method should be a valid complementary and alternative therapy in the management of diabetic nephropathy, especially in improving UAER, serum creatinine, fasting blood glucose, and beta-2 microglobulin. However, more studies with long follow-up are warrant to confirm the current findings. Hindawi Publishing Corporation 2016 2016-05-30 /pmc/articles/PMC4904113/ /pubmed/27313643 http://dx.doi.org/10.1155/2016/3257603 Text en Copyright © 2016 Jiao Ying Ou et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ou, Jiao Ying Huang, Di Wu, Yan Sheng Xu, Lin He, Fei Wang, Hui Ling Shi, Li Qiang Wan, Qiang He, Li Qun Dong Gao, Jian A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy |
title | A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy |
title_full | A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy |
title_fullStr | A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy |
title_full_unstemmed | A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy |
title_short | A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy |
title_sort | meta-analysis of randomized controlled trials of yiqi yangyin huoxue method in treating diabetic nephropathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904113/ https://www.ncbi.nlm.nih.gov/pubmed/27313643 http://dx.doi.org/10.1155/2016/3257603 |
work_keys_str_mv | AT oujiaoying ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT huangdi ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT wuyansheng ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT xulin ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT hefei ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT wanghuiling ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT shiliqiang ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT wanqiang ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT heliqun ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT donggaojian ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT oujiaoying metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT huangdi metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT wuyansheng metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT xulin metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT hefei metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT wanghuiling metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT shiliqiang metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT wanqiang metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT heliqun metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy AT donggaojian metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy |